Online first
Short communication
Published online: 2024-04-22
Echocardiographic screening for liver steatosis
Pubmed: 38712773
Abstract
Not available
References
- Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7(9): 851–861.
- Le P RM, Gawieh S, McCullough AJ, et al. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study. Hepatology. 2020; 72.
- Mantovani A, Scorletti E, Mosca A, et al. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020; 111S: 154170.
- Johnson SI, Fort D, Shortt KJ, et al. Ultrasound Stratification of Hepatic Steatosis Using Hepatorenal Index. Diagnostics (Basel). 2021; 11(8).
- Duell PB, Welty FK, Miller M, et al. American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022; 42(6): e168–e185.
- Gorczyca-Głowacka I, Wełnicki M, Mamcarz A, et al. Metabolic associated fatty liver disease and cardiovascular risk: The expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society. Kardiol Pol. 2023; 81(2): 207–214.
- Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology. 2022; 163(3): 764–774.e1.
- Xie Y, Kong W, Wang X, et al. Association of glycated hemoglobin with non-alcoholic fatty liver disease patients and the severity of liver steatosis and fibrosis measured by transient elastography in adults without diabetes. BMC Endocr Disord. 2022; 22(1): 220.
- Colosimo S, Tan GD, Petroni ML, et al. Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent. Nutr Metab Cardiovasc Dis. 2023; 33(3): 640–648.
- Finer N. Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. Diabetes Obes Metab. 2022; 24 Suppl 2: 44–54.
- Singal AK, Bataller R, Ahn J, et al. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018; 113(2): 175–194.
